Chardan Capital Reiterates “Buy” Rating for Immuneering (NASDAQ:IMRX)

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report issued on Monday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Immuneering in a research report on Friday, March 21st. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th.

Immuneering Stock Performance

IMRX opened at $1.69 on Monday. The stock has a market capitalization of $52.47 million, a PE ratio of -0.86 and a beta of -0.32. The stock’s 50 day moving average price is $1.78 and its 200-day moving average price is $2.01. Immuneering has a 52-week low of $1.00 and a 52-week high of $3.83.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.16). Research analysts forecast that Immuneering will post -1.86 EPS for the current fiscal year.

Institutional Trading of Immuneering

A number of hedge funds have recently made changes to their positions in IMRX. Southport Management L.L.C. increased its position in Immuneering by 4.9% during the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after buying an additional 10,000 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Immuneering during the fourth quarter valued at $390,000. HighTower Advisors LLC raised its position in shares of Immuneering by 33.7% in the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock worth $157,000 after purchasing an additional 18,000 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after purchasing an additional 22,400 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after purchasing an additional 10,126 shares during the last quarter. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.